R
Robert W. Dugger
Researcher at Pfizer
Publications - 31
Citations - 1087
Robert W. Dugger is an academic researcher from Pfizer. The author has contributed to research in topics: Enantiomer & Isopropyl. The author has an hindex of 9, co-authored 31 publications receiving 948 citations.
Papers
More filters
Journal ArticleDOI
Large-scale oxidations in the pharmaceutical industry.
Journal ArticleDOI
Survey of GMP Bulk Reactions Run in a Research Facility between 1985 and 2002
TL;DR: A review of reactions scaled in the GMP facilities at the Pfizer-Groton site was undertaken as mentioned in this paper, where reactions were categorized into one of seven categories: carbon−carbon bond formation, carboxylic acid derivative interconversion, carbon−nitrogen bond formation and carbon−oxygen bond formation.
Journal ArticleDOI
Asymmetric Synthesis of the Cholesteryl Ester Transfer Protein Inhibitor Torcetrapib
TL;DR: In this article, the authors reported synthetic efforts used to synthesize kilogram quantities of the cholesteryl ester transfer protein (CETP) inhibitor torcetrapib, via a mid-stage resolution.
Journal ArticleDOI
Synthesis of the CETP Inhibitor Torcetrapib: The Resolution Route and Origin of Stereoselectivity in the Iminium Ion Cyclization
David B. Damon,Robert W. Dugger,Magnus-Aryitey George Tetteh,Roger B. Ruggeri,Wester Ronald Thure,Meihua Tu,Yuriy A. Abramov +6 more
TL;DR: In this article, a practical, efficient synthesis of (−)-(2R,4S)-4-[(3,5-bis-trifluoromethyl-benzyl)methoxycarbonylamino]-2-ethyl-6-TRF-3,4-dihydro-2H-quinoline-1 carboxylic acid ethyl ester (1), a cholesteryl esters transfer protein (CETP) inhibitor, is described.
Journal ArticleDOI
Developing an Asymmetric Transfer Hydrogenation Process for (S)-5-Fluoro-3-methylisobenzofuran-1(3H)-one, a Key Intermediate to Lorlatinib
Shengquan Duan,Bryan Li,Robert W. Dugger,Brian G. Conway,Rajesh Kumar,Carlos A. Martinez,Teresa W. Makowski,Robert Pearson,Mark Olivier,Roberto Colon-Cruz +9 more
TL;DR: In this article, the synthesis of (S)-5-fluoro-3-methylisobenzofuran-1(3H)-one, a key intermediate to lorlatinib, is described.